Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Open accessPublished version of a preprint
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 2 of the 7 sources its claims cite were checked for support.
Abstract
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, VOC 202012/01 (lineage B.1.1.7), emerged in southeast England in September 2020 and is rapidly spreading toward fixation. Using a variety of statistical and dynamic modeling approaches, we estimate that this variant has a 43 to 90% (range of 95% credible intervals, 38 to 130%) higher reproduction number than preexisting variants. A fitted two-strain dynamic transmission model shows that VOC 202012/01 will lead to large resurgences of COVID-19 cases. Without stringent control measures, including limited closure of educational institutions and a greatly accelerated vaccine rollout, COVID-19 hospitalizations and deaths across England in the first 6 months of 2021 were projected to exceed those in 2020. VOC 202012/01 has spread globally and exhibits a similar transmission increase (59 to 74%) in Denmark, Switzerland, and the United States.
Overview
CoChat Summary
TL;DR
Using sequencing, mobility/contact data, and dynamic transmission models, the paper finds that SARS-CoV-2 lineage B.1.1.7 (VOC 202012/01) spread substantially faster than prior lineages in England. The authors estimate it is 43 to 90% more transmissible, with no clear evidence of increased disease severity, but warn that faster spread would increase cases, hospitalizations, and the need for stronger control measures and faster vaccination.
Key findings
- In UK sequencing data, VOC 202012/01 had the highest relative population growth rate among 307 other lineages in the first 31 days after initial phylogenetic observation, and it continued to expand.
- A multinomial spline model estimated an increased growth rate of +0.104 day–1 relative to B.1.177, corresponding to a 77% increase in reproduction number R (95% CI, 73 to 81%) assuming a 5.5-day generation interval.
- Alternative analyses estimated R for VOC 202012/01 to be 43% higher (95% CI, 38 to 48%) from case-based regression, and 55% higher in Denmark, 74% higher in Switzerland, and 59% higher in the United States.
- The transmission model found no clear increase or decrease in severity, with odds ratios of 0.92 for hospitalization, 0.90 for critical illness, and 0.90 for death, but estimated transmissibility was 65% higher in the three most affected NHS regions and 82% higher across all seven regions.
Methods
- The study combined publicly available sequencing data from COG-UK, Pillar 2 testing data for S gene target failure, mobility data from Google Community Mobility, and social contact data from the CoMix survey, plus analogous sequence/RT-PCR data from Denmark, Switzerland, and the US.
- The authors used multinomial and binomial generalized linear mixed models, negative binomial state-space models, and an age- and region-structured deterministic compartmental transmission model fitted to multiple regional data streams, including deaths, hospital admissions, bed occupancy, PCR prevalence, seroprevalence, and VOC frequency.
- They compared five mechanistic hypotheses for the rapid spread, assessed model fit with deviance information criteria and short-term prediction, and ran scenario projections under varying NPIs and vaccination rollout rates.
Limitations
- The paper states that only a small number of intervention and vaccination scenarios were considered, and these should not be viewed as the only policy options.
- It states that the transmission model does not explicitly capture nursing home or hospital transmission, and regions were fit separately rather than jointly modeling between-region transmission.
- It notes uncertainty in model choice and parameter assumptions, including school-closure assumptions and NPI efficacy; these are limitations stated in the paper.
- Evident from the text: the severity analysis is based on early population-level data up to 24 December 2020, so delays from infection to hospitalization or death could obscure severity effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 2 Measuring the growth rate of VOC 202012/01. (A) Average relativized growth rate (i.e., a measure of variant fitness relative to other variants present during the 31 days after initial phylogenetic observation of a given variant) for all lineages in the COG-UK dataset, highlighting many lineages that have risen to prominence including B.1.177, the lineage with the highest relative abundance during the initial phylogenetic observation of VOC 202012/01. The shaded regions show conservative 95% rejection intervals; VOC 202012/01 is the first strain to exceed this threshold of faster relativized growth. Although many lineages exhibit above-average rates of growth, VOC 202012/01 has had the highest average relativized growth of any lineage in the history of COG-UK surveillance of SARS-COV-2. (B) Plotting all lineages’ relativized growth rates [ρ(t)] as a function of lineage age with conservative 95% rejection intervals highlights the significantly faster growth of VOC 202012/01 relative to other lineages at comparable times since their initial observation. Later declines in VOC and B.1.177 correspond to highly uncertain estimates of growth rates for data that are yet to be backfilled, so these declines in ρ(t) are sensitive to the processing of future sequences from recent dates (fig. S1). (C) Muller plots of the relative abundances of the major SARS-CoV-2 variants in the UK, based on a multinomial spline fit to COG-UK sequence data (Table 1 and table S1, separate-slopes multinomial spline model). A model extrapolation until 1 March 2021 is shown (shaded area). Minority variants are 440 circulating SARS-CoV-2 variants of low abundance. Specific colors represent the same lineages in (A) to (C). (D) Mean reproduction number over 7-day periods in 149 upper-tier local authorities of England (colored by the NHS England region they are within) plotted against the weekly proportion of Pillar 2 community SARS-CoV-2 tests with S gene target failure shows the spread of VOC 202012/01, a corresponding increase in the reproduction number in each local authority, and the eventual impact of targeted government restrictions from 20 December 2020. Testing data are shown for the week after the reproduction number estimates to account for delays from infection to test.](https://figures.cochat.ai/paper-figures/6a959b32b94b41a4aab77f4b47b25a40/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-2.jpg)
![Fig. 3 Comparison of possible biological mechanisms underlying the rapid spread of VOC 202012/01. Each row shows a different assumed mechanism. (A) Relative frequency of VOC 202012/01 (black line and ribbon respectively denote observed S gene target failure frequency with 95% binomial credible interval; purple line and ribbon respectively denote mean and 95% credible interval from model fit). (B) Posterior estimates (mean and 95% credible intervals) for relative odds of hospitalization (severe illness), relative odds of ICU admission (critical illness), relative odds of death (fatal illness), growth rate as a multiplicative factor per week [i.e., exp(7·∆r)], and the parameter that defines the hypothesized mechanism; all parameters are relative to those estimated for preexisting variants. (C to E) Illustrative model fits for the South East NHS England region: (C) fitted two-strain increased transmissibility model with VOC 202012/01 included; (D) fitted two-strain increased transmissibility model with VOC 202012/01 removed; (E) fitted single-strain model without emergence of VOC 202012/01. Black lines denote observed data; error bars denote the date range and 95% credible intervals for observed PCR prevalence and seroprevalence; colored lines and ribbons denote median and 95% credible intervals from model fit.](https://figures.cochat.ai/paper-figures/806d848e45ca40c19e0cc853e2b24dfc/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-3.jpg)

Verification
Claims the paper makes
2 Valid · 0 Not valid · 4 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“we did not find substantial differences in social interactions between regions of high and low VOC 202012/01 prevalence, as measured by Google mobility (11) and social contact survey data (12) from September to December 2020 (Fig. 1, E and F).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
What the sources say
- Not matchedcites [11]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Methods (Survey methodology) identify this as the CoMix social-contact survey, supporting the citation’s identification of the survey. But the Results (Participant characteristics) say the data reported here were collected on 24–27 March 2020; this paper does not establish that its reported data cover September–December 2020. The comparison between regions is presented as the citing authors’ own finding, not a finding attributed to this source. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This yielded an estimated increase in R for VOC 202012/01 of 43% (95% CI, 38 to 48%), increasing to a 57% (95% CI, 52 to 62%) increase if the spline was not included (Table 1, models 4a and 4b).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants.”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Discussion Combining multiple behavioral and epidemiological data sources with statistical and dynamic modeling, we estimated that the SARS-CoV-2 variant VOC 202012/01 has a 43 to 90% (range of 95% CrIs, 38 to 130%) higher reproduction number than preexisting variants of SARS-CoV-2 in England, assuming no changes to the generation interval. On the basis of early population-level data, we were unable to identify whether the new variant is associated with higher disease severity. Theoretical considerations suggest that, in some cases, natural selection may favor reduced severity of disease in pathogens (23). For this to be true, however, the pathogen’s infectious period must be truncated by disabling symptoms or death often enough that a less-virulent mutant generates more secondary infections despite potentially being less transmissible per contact, to the extent that decreased virulence and decreased transmissibility are consequences of the same mutation (e.g., one that decreases viral load). It is far from clear that this condition holds for SARS-CoV-2, given substantial transmission before the onset of severe symptoms. Regardless, without strengthened controls, there is a clear risk that future epidemic waves may be larger—and hence associated with greater burden—than previous waves. The UK government initiated a third national lockdown on 5 January 2021 in response to the rapid spread of VOC 202012/01, including school closures. Educational settings are among the largest institutions linked to SARS-CoV-2 clusters that remained open during the November 2020 lockdown (24), which means that the enacted school and university closures may have substantially assisted in reducing the burden of COVID-19 in early 2021. The increase in transmission associated with VOC 202012/01 has crucial implications for vaccination. First, it means that prompt and efficient vaccine delivery and distribution are even more important to reduce the impact of the pandemic in the near future. Increased transmission resulting from VOC 202012/01 will raise the herd immunity threshold, so that the potential burden of SARS-CoV-2 is larger and higher vaccine coverage will be required to achieve herd immunity. It is therefore extremely concerning that VOC 202012/01 has spread to at least 114 countries globally (2). Although VOC 202012/01 was first identified in England, a rapidly spreading variant has also been detected in South Africa (25, 26), where there was a marked increase in transmission in late 2020. Another variant exhibiting immune escape has emerged in Brazil (27, 28). Thus, vaccination timelines will also be a crucial determinant of future burden in other countries where similar new variants are present. Second, there is a need to assess how VOC 202012/01 and other emerging lineages affect the efficacy of vaccines (29, 30). Vaccine developers may need to consider developing formulations with variant sequences, and they may want to initiate post-licensure studies to detect differences in efficacy between the preexisting and new variants. Licensing authorities may need to clarify abbreviated pathways to marketing for vaccines that involve altering strain formulation without any other changes to their composition. There are limitations to our analysis. We have considered a small number of intervention and vaccination scenarios, which should not be regarded as the only available options for policy-makers. Our transmission model does not explicitly capture nursing home or hospital transmission of SARS-CoV-2, and we fit the model to each region of England separately rather than pooling information across regions and explicitly modeling transmission between regions. There are also uncertainties in the choice of model used to generate these predictions, and the exact choice will yield differences in the measures needed to control the epidemic. We note that even without increased susceptibility of children to VOC 202012/01, the more efficient spread of the variant implies that the difficult societal decision of closing schools will be a key public health question for multiple countries in the months ahead. We only assess relative support in the data for the mechanistic hypotheses proposed, but there may be other plausible mechanisms driving the resurgence of cases that we did not consider, and we have not identified the specific combination of mechanisms driving the increased transmission of VOC 202012/01. We identify increased transmissibility as the most parsimonious mechanistic explanation for the higher growth rate of VOC 202012/01, but a longer infectious period also fits the data well (table S4) and is supported by longitudinal testing data (17). Our conclusions about school closures were based on the assumption that children had reduced susceptibility and infectiousness relative to adults (19), but the precise values of these parameters and the impact of school closures remain the subject of scientific debate (31). We based our assumptions about the efficacy of NPIs on the measured impact on mobility of previous national lockdowns in England, but the impact of policy options cannot be predicted with certainty. Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants. Our modeling analysis suggests that this difference could be explained by an overall higher infectiousness of VOC 202012/01, but not by a shorter generation time or immune escape alone. Further experimental work will provide insight into the biological mechanisms for our observations, but given our projections of a rapid rise in incidence from VOC 202012/01—and the detection of other novel and highly transmissible variants (25–28)—there is an urgent need to consider what new approaches may be required to sufficiently reduce the ongoing transmission of SARS-CoV-2.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that the relative population growth rate of VOC 202012/01 in the first 31 days after its initial phylogenetic observation was higher than that of all 307 other lineages with enough observations to obtain reliable growth-rate estimates (Fig. 2A and fig. S1).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
plainn = 150,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of COVID-19 cases attributable to VOC 202012/01 increased rapidly in all regions of England, following an initial expansion in the southeast (Fig. 1A)”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 43 claims and every source verdict.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“B.1.1.7 to be between 43% and 82%3 more transmissible than preexisting variants in the United Kingdom.”
From New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, viral variants of concern have emerged in the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50–55).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several emerging viral variants of concern have been identified that have mutations in the spike protein, including the B.1.1.7 variant (originating from the UK and which has eight spike mutations92), the B.1.351 variant (originating from South Africa) and the P.1 variant (originating from Brazil and which also contains multiple mutations in the spike protein and is spreading widely)57,93.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiological studies suggest that it was approximately 50% more transmissible than previously circulating UK variants 191,197,198 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [198]
The cited source says what the claim attributes to it.
In the citing paper
“it has been previously reported that B.1.1.7 is associated with lower Ct values, corresponding to higher VLs 3”
From Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals (2021) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
Markov Processes: Characterization and Convergence
Ethier, S. N., & Kurtz, T. G. (1986) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316658 · Cited by 3,634
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
Advanced Bayesian Multilevel Modeling with the R Package brms
Bürkner, P.-C. (2018) · The R Journal · doi:10.32614/rj-2018-017 · Cited by 3,015 · cited 9×
“168) 67 (53-83) 120 (92-152) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE North West VOC vs.”
BackgroundMethodInfluentialSocial Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases
Mossong, J., Hens, N., Jit, M., Beutels, P., Auranen, K., Mikolajczyk, R., Massari, M., Salmaso, S., Tomba, G. S., Wallinga, J., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050074 · Cited by 2,900 · cited 10×
“105) 43 (40-46) 72 (67-78) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London VOC vs.”
BackgroundInfluentialSelf-citationProjecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611 · cited 8×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundResultInfluentialEstimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Self-citationA dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 10×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundInfluential
Cited by
Items 401–500 of 2,327
Empirical examples demonstrate how relational thinking might enrich science and practice
Eyster, H. N., Satterfield, T. A., & Chan, K. M. A. (2023) · People and Nature · doi:10.1002/pan3.10453 · Cited by 62
Human Organoids and Organs‐on‐Chips for Addressing COVID‐19 Challenges
Wang, Y., Wang, P., & Qin, J. (2022) · Advanced Science · doi:10.1002/advs.202105187 · Cited by 51
Chen, L., Lu, L., Choi, C. Y.-K., Cai, J., Tsoi, H., Chu, A. W., Ip, J. D., Chan, W.-M., Zhang, R., Zhang, X., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab656 · Cited by 52
Emergence of an early SARS-CoV-2 epidemic in the United States
Zeller, M., Gangavarapu, K., Anderson, C., Smither, A. R., Vanchiere, J. A., Rose, R., Snyder, D. J., Dudas, G., Watts, A., Matteson, N. L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.030 · Cited by 58
“Lineage prevalence during the epidemic in the United States, related to Figure 6 Lineage prevalence of B.1, B.1.2, and B.1.1.7 in the United States, Louisiana and other U.S states from March 2020 until April 2021. ll Article 1e+02 1e+03 1e+04 1e+05 1e+01 1e+02 1e+03 1e+04 1e+05 Air travel passenger volume Alaska Arizo…”
InfluentialÇelik, İ., Yadav, R., Düzgün, Z., Albogami, S. M., El‐Shehawi, A. M., Fatimawali, F., Idroes, R., Tallei, T. E., & Emran, T. B. (2021) · Biology · doi:10.3390/biology10090880 · Cited by 52
A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies
Sánchez‐Zuno, G. A., Matuz-Flores, M. G., González-Estévez, G., Nicoletti, F., Turrubiates‐Hernández, F. J., Mangano, K., & Muñóz-Valle, J. F. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211050199 · Cited by 50
“The N501Y mutation is one of the six key contact residues within the RBD.78 This change in different fundamental residues in the binding site could affect the fusion of the host cells–virus and, therefore, the infectivity of the virus.79 As of December 28, 2020, this variant accounted for approximately 28% of cases of…”
BackgroundInfluentialFitness, growth and transmissibility of SARS-CoV-2 genetic variants
Volz, E. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00610-z · Cited by 60
Lin, X., Glier, M. B., Kuchinski, K. S., Mierlo, T. R.-V., McVea, D., Tyson, J. R., Prystajecky, N., & Ziels, R. M. (2021) · mSystems · doi:10.1128/msystems.01068-21 · Cited by 52
Park, S. W., Bolker, B. M., Funk, S., Metcalf, C. J. E., Weitz, J. S., Grenfell, B. T., & Dushoff, J. G. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0173 · Cited by 49
“Modelling studies have also considered the possibility that the observed fast replacement of some variants may be driven, in part, by shorter generation intervals [2,6].”
BackgroundInfluentialSelf-citationMohammad, A., Abubaker, J. A., & Al‐Mulla, F. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198522 · Cited by 45
Yuan, Y., Deng, Z., Chen, M., Yin, D., Zheng, J., Liu, Y., Liu, X., Zou, H., Zhang, C., & Sun, C. (2021) · Vaccines · doi:10.3390/vaccines9091044 · Cited by 53
“Coronavirus disease 2019 (COVID-19) continues to spread worldwide, and the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants further brings new challenges in the prevention and control of the global pandemic [1,2].”
BackgroundPavot, V., Berry, C., Kishko, M., Anosova, N. G., Huang, D., Tibbitts, T., Raillard, A., Gautheron, S., Gutzeit, C., Koutsoukos, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29219-2 · Cited by 47
Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein
Gerdol, M., Dishnica, K., & Giorgetti, A. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198674 · Cited by 47
Aganović, A., Cao, G., Kurnitski, J., & Wargocki, P. L. (2022) · Building and Environment · doi:10.1016/j.buildenv.2022.109924 · Cited by 53
Lassaunière, R., Fonager, J., Rasmussen, M., Frische, A., Polacek, C., Rasmussen, T. B., Lohse, L., Belsham, G. J., Underwood, A., Winckelmann, A. A., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.698944 · Cited by 46
Wollschläger, P., Tödt, D., Gerlitz, N., Pfaender, S., Bollinger, T., Sing, A., Dangel, A., Ackermann, N., Korn, K., Ensser, A., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.025 · Cited by 48
“7 variant has been associatedwith increasedmortality [4] and risk of transmission [5] and is rapidly expanding its geographic range worldwide.”
A highly potent antibody effective against SARS-CoV-2 variants of concern
Fenwick, C. W., Turelli, P., Perez, L. H., Pellaton, C., Esteves-Leuenberger, L., Farina, A., Campos, J., Lana, E., Fiscalini, F., Raclot, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109814 · Cited by 52
“The B.1.1.7 variant (also called 501Y.V1) first identified in the UK contains mutations that augment virus transmission rates by 65%–74% (Davies et al., 2021; Volz et al., 2021), launching in late 2020 a wave of infections that rapidly spread in many regions of the world.”
InfluentialInjectable Slow-Release Hydrogel Formulation of a Plant Virus-Based COVID-19 Vaccine Candidate
Nkanga, C. I., Ortega-Rivera, O. A., Shin, M. D., Moreno‐Gonzalez, M. A., & Steinmetz, N. F. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00112 · Cited by 47
Servellita, V., Morris, M. K., Sotomayor-González, A., Gliwa, A. S., Torres, E., Brazer, N., Zhou, A. Y., Hernandez, K., Sankaran, M., Wang, B., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01041-4 · Cited by 48
Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies
Rouzine, I. M., & Rozhnova, G. (2023) · Communications Medicine · doi:10.1038/s43856-023-00320-x · Cited by 54
“R 0 is larger than 1 for the original SARS-CoV-2 variant (range 1.9 – 6.5) 76 and for Alpha, Delta, Gamma, Omicron and other VOCs 8,9,11,77 .”
InfluentialMolecular insights into the adaptive evolution of SARS-CoV-2 spike protein
Yao, Z., Zhang, L., Duan, Y., Tang, X., & Lü, J. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106121 · Cited by 52
Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
Chen, C., Nadeau, S., Topolsky, I., Manceau, M., Huisman, J. S., Jablonski, K. P., Fuhrmann, L., Dreifuss, D., Jahn, K., Beckmann, C., et al. (2021) · Epidemics · doi:10.1016/j.epidem.2021.100480 · Cited by 44
“Instead, B.1.1.7’s rapid increase in frequency in many high-prevalence regions across the UK in parallel is well-explained by a transmission fitness advantage (Davies et al., 2021).”
InfluentialStructure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
Mehra, R., & Kepp, K. P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00433 · Cited by 45
The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
Pérez-Gómez, R. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040058 · Cited by 47
Fröba, M., Große, M., Setz, C., Rauch, P., Auth, J., Spanaus, L., Münch, J., Ruétalo, N., Schindler, M., Morokutti-Kurz, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413202 · Cited by 50
Dikdan, R. J., Marras, S. A. E., Field, A. P., Brownlee, A., Cironi, A., Hill, D. A., & Tyagi, S. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.01.004 · Cited by 48
Yang, Z. L., Zhang, S., Tang, Y., Zhang, S., Xu, D.-Q., Yue, S., & Liu, Q. (2022) · Aging and Disease · doi:10.14336/ad.2021.1210 · Cited by 51
Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
Hoteit, R., & Yassine, H. M. (2022) · Vaccines · doi:10.3390/vaccines10060919 · Cited by 51
“The N501Y, K417N, and E484K mutations, which are likewise present in the Alpha and Beta forms, have been linked to higher binding affinity to human ACE2 and transmissibility [104,187,210].”
BackgroundInfluentialEmergence of SARS-CoV-2 Variants in the World: How Could This Happen?
Parra-Lucares, A., Segura, P., Rojas, V. A., Pumarino, C., Saint-Pierre, G., & Toro, L. (2022) · Life · doi:10.3390/life12020194 · Cited by 54
Nanoparticles in clinical trials of COVID-19: An update
Rauf, A., Abu‐Izneid, T., Khalil, A. A., Hafeez, N., Olatunde, A., Rahman, M. M., Semwal, P., Al-Awthan, Y. S., Bahattab, O. S., Khan, I. N., et al. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106818 · Cited by 49
Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa
Pearson, C. A. B., Silal, S. P., Li, M. W. Z., Dushoff, J., Bolker, B. M., Abbott, S., van Schalkwyk, C., Davies, N. G., Barnard, R. C., Edmunds, W. J., et al. (2021) · doi:10.1101/2021.12.19.21268038 · Cited by 44
Self-citationSeroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19
Dabisch, P. A., Biryukov, J., Beck, K., Boydston, J. A., Sanjak, J. S., Herzog, A., Green, B., Williams, G., Yeager, J. J., Bohannon, J. K., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009865 · Cited by 45
Pople, D., Monk, E. J. M., Evans, S., Foulkes, S., Islam, J., Wellington, E., Atti, A., Hope, R., Robotham, J. V., Hopkins, S., et al. (2022) · BMJ · doi:10.1136/bmj-2022-070379 · Cited by 45
Moalla, M., & Dammak, S. (2023) · Journal of Global Responsibility · doi:10.1108/jgr-07-2022-0061 · Cited by 70
SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
Hattab, D., Amer, M. F. A., Al‐Alami, Z. M., & Bakhtiar, A. (2024) · Infection · doi:10.1007/s15010-024-02223-y · Cited by 51
“2) [23].”
BackgroundMeyers, L. M., Gutiérrez, A. H., Boyle, C., Terry, F. E., McGonnigal, B., Salazar, A. Μ., Princiotta, M. F., Martin, W. D., Groot, A. S. D., & Moise, L. (2021) · npj Vaccines · doi:10.1038/s41541-021-00331-6 · Cited by 44
Modelling airborne transmission of SARS-CoV-2 using CARA: risk assessment for enclosed spaces
Henriques, A., Mounet, N., Aleixo, L., Elson, P., Devine, J., Azzopardi, G., Andreini, M., Rognlien, M., Tarocco, N., & Tang, J. W.-T. (2022) · Interface Focus · doi:10.1098/rsfs.2021.0076 · Cited by 56
“While preliminary laboratory results indicated evidence for higher viral load in infected individuals [24], it now appears that these elevated values were not substantiated by more recent studies [25].”
ResultCorbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’ Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · doi:10.1101/2021.04.20.440647 · Cited by 43
“7 variant (21), which is 133 highly transmissible and currently circulating around the world (22), was not appreciably 134 decreased as compared to D614G (Fig.”
BackgroundInternational consensus on lung function testing during the COVID-19 pandemic and beyond
McGowan, A., Laveneziana, P., Bayat, S., Beydon, N., Boros, P. W., Burgos, F., Fležar, M., Franczuk, M., Galarza-Jimenez, M.-A., Kendrick, A. H., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00602-2021 · Cited by 45
Peng, L., Hu, Y., Mankowski, M. C., Ren, P., Chen, R. E., Wei, J., Zhao, M., Li, T., Tripler, T. N., Ye, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29288-3 · Cited by 43
The past, current and future epidemiological dynamic of SARS-CoV-2
Balloux, F., Tan, C., Swadling, L., Richard, D., Jenner, C., Maini, M., & van Dorp, L. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac003 · Cited by 41
“The more transmissible Alpha VoC, which emerged in the UK, spread globally [18, 19].”
BackgroundA comparative overview of SARS‑CoV‑2 and its variants of concern
Ahmad, A., Fawaz, M. A. M., & Aisha, A. (2022) · Infezioni in Medicina · doi:10.53854/liim-3003-2 · Cited by 70
A protein language model for exploring viral fitness landscapes
Ito, J., Strange, A. P., Liu, W., Joas, G., Lytras, S., Matsuno, K., Nao, N., Sawa, H., Mizuma, K., Kojima, I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59422-w · Cited by 62
“Second, the logistic model used to estimate variant fi tness operates under a strong assumption that the relative fi tness among variants remains constant over time 4,20 – 22 .”
Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada
VILCHES, T. N., Zhang, K., Exan, R. V., Langley, J. M., & Moghadas, S. M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.058 · Cited by 42
Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model
Gog, J. R., Hill, E. M., Danon, L., & Thompson, R. N. (2021) · Royal Society Open Science · doi:10.1098/rsos.210530 · Cited by 54
“Furthermore, estimates for COVID-19 severity vary between studies, depending on context [30–32] and the presence of more pathogenic variants [6,8].”
Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 Variants
Zupancic, J. M., Schardt, J. S., Desai, A. A., Makowski, E. K., Smith, M. D., Pornnoppadol, G., Barbosa, M. G. D. M., Cascalho, M., Lanigan, T. M., & Tessier, P. M. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100099 · Cited by 43
COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective
Marcelin, J. R., Pettifor, A. E., Janes, H., Brown, E. R., Kublin, J. G., & Stephenson, K. E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac124 · Cited by 45
“This variant was found to be 50%–75% more transmissible than previously circulating strains and had a higher secondary attack rate [44, 45].”
BackgroundChatterjee, B., Sandhu, H. S., & Dixit, N. M. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010630 · Cited by 42
SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice
Lee, K. S., Wong, T. Y., Russ, B. P., Horspool, A. M., Miller, O. A., Rader, N. A., Givi, J. P., Winters, M. T., Wong, Z. Y., Cyphert, H. A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273430 · Cited by 45
Epidemic spreading under mutually independent intra- and inter-host pathogen evolution
Zhang, X., Ruan, Z., Zheng, M., Zhou, J., Boccaletti, S., & Barzel, B. (2022) · Nature Communications · doi:10.1038/s41467-022-34027-9 · Cited by 48
Dagpunar, J. S. (2021) · medRxiv · doi:10.1101/2021.06.03.21258293 · Cited by 43
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
Yu, J., Tostanoski, L. H., Mercado, N. B., McMahan, K., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Atyeo, C. G., Martinez, D. R., Anioke, T., et al. (2021) · Nature · doi:10.1038/s41586-021-03732-8 · Cited by 37
Superspreading in the emergence of COVID-19 variants
Gómez‐Carballa, A., Pardo‐Seco, J., Bello, X., Martinón‐Torres, F., & Salas, A. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.09.003 · Cited by 45
“7 can be explained by the large number of favorable mutations accumulated by this variant [24].”
InfluentialNasally inhaled therapeutics and vaccination for COVID‐19: Developments and challenges
Xi, J., Lei, L. R., Zouzas, W., & Si, X. A. (2021) · MedComm · doi:10.1002/mco2.101 · Cited by 48
Francis, R. V., Billam, H., Clarke, M., Yates, C., Tsoleridis, T., Berry, L., Mahida, N., Irving, W. L., Moore, C., Holmes, N., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab483 · Cited by 43
Carroll, T. D., Fox, D., van Doremalen, N., Ball, E. E., Morris, M. K., Sotomayor-González, A., Servellita, V., Rustagi, A., Yinda, C. K., Fritts, L., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1009914 · Cited by 40
Comparison of the 2021 COVID-19 roadmap projections against public health data in England
Keeling, M. J., Dyson, L., Tildesley, M. J., Hill, E. M., & Moore, S. (2022) · Nature Communications · doi:10.1038/s41467-022-31991-0 · Cited by 44
Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021
Lai, A., Bergna, A., Menzo, S., Zehender, G., Caucci, S., Ghisetti, V., Rizzo, F. M., Maggi, F., Cerutti, F., Giurato, G., et al. (2021) · Virology Journal · doi:10.1186/s12985-021-01638-5 · Cited by 41
“7) was first identified in the UK from a sample obtained in late September 2020 [2, 3] (https:// www.”
BackgroundEvolution of the SARS-CoV-2 genome and emergence of variants of concern
Safari, I., & Elahi, E. (2021) · Archives of Virology · doi:10.1007/s00705-021-05295-5 · Cited by 44
Veneti, L., Valcarcel Salamanca, B., Seppälä, E., Starrfelt, J., Storm, M. L., Bragstad, K., Hungnes, O., Bøås, H., Kvåle, R., Vold, L., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.12.321 · Cited by 41
Munday, J. D., Jarvis, C. I., Gimma, A., Wong, K. L., van Zandvoort, K., CMMID COVID-19 Working Group, Liu, Y., Hellewell, J., Davies, N. G. M., Villabona‐Arenas, C. J., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02107-0 · Cited by 45
“To give insight into the difference in contacts of adults and children between the two periods of lockdown, we include a brief descriptive analysis of the contacts recorded during the November and January lockdown periods by age group and geographical region.”
BackgroundInfluentialSelf-citationNandakumar, V., Profaizer, T., Lozier, B. K., Elgort, M., Larragoite, E. T., Williams, E. S. C. P., Solis‐Leal, A., Lopez, J., Berges, B. K., Planelles, V., et al. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0213-sa · Cited by 40
Genetic Analysis of SARS-CoV-2 Variants in Mexico during the First Year of the COVID-19 Pandemic
Taboada, B., Zárate, S., Iša, P., Boukadida, C., Vázquez-Pérez, J. A., Muñoz‐Medina, J. E., Ramírez–González, J. E., Comas‐García, A., Grajales-Muñíz, C., Rincón-Rubio, A., et al. (2021) · Viruses · doi:10.3390/v13112161 · Cited by 44
Alves, P. A., de Oliveira, E. G., Franco-Luiz, A. P. M., Almeida, L. T., Gonçalves, A. B., Borges, I. A., Rocha, F. D. S., Rocha, R. P., Bezerra, M. F., Miranda, P., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.713713 · Cited by 43
Improving local prevalence estimates of SARS-CoV-2 infections using a causal debiasing framework
Nicholson, G., Lehmann, B., Padellini, T., Pouwels, K. B., Jersakova, R., Lomax, J., King, R., Mallon, A., Diggle, P. J., Richardson, S. T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-01029-0 · Cited by 50
Gómez‐Carballa, A., Calle, I. R., Pardo‐Seco, J., Rial, J. G., Rivero-Velasco, C., Rodríguez‐Núñez, N., Barbeito‐Castiñeiras, G., Pérez-Freixo, H., Cebey‐López, M., Barral‐Arca, R., et al. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112890 · Cited by 48
Rathnasinghe, R., Jangra, S., Ye, C., Čupić, A., Singh, G., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30763-0 · Cited by 43
Hirotsu, Y., & Omata, M. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009619 · Cited by 50
Zelyas, N. J., Pabbaraju, K., Croxen, M. A., Lynch, T., Buss, E., Murphy, S. A., Shokoples, S., Wong, A. A., Kanji, J. N., & Tipples, G. A. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00315-21 · Cited by 38
Lu, L., Chu, A. W., Zhang, R., Chan, W.-M., Ip, J. D., Tsoi, H., Chen, L., Cai, J., Lung, D. C., Tam, A. R., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103544 · Cited by 39
“Since November 2020, several variants bearing mutations in the spike RBD have rapidly spread in the United Kingdom (B. [17,18], and a higher viral load is found in patients with the B.1.1.7 variant [19].”
InfluentialSetiadi, W., Rozi, I. E., Safari, D., Daningrat, W. O. D., Johar, E., Yohan, B., Yudhaputri, F. A., Lestari, K. D., Oktavianthi, S., Myint, K. S. A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268241 · Cited by 40
“The recent emergence of more transmissible variants, such as the Alpha and Delta variants, put an additional burden on the government effort to contain COVID-19 [8,9].”
BackgroundDutta, D., Liu, J., & Xiong, H. (2022) · PubMed · Cited by 50
Tracking SARS-COV-2 variants using Nanopore sequencing in Ukraine in 2021
Yakovleva, A., Kovalenko, G., Redlinger, M., Liulchuk, M. G., Bortz, E., Задорожна, В. І., Scherbinska, A. M., Wertheim, J. O., Goodfellow, I., Meredith, L. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19414-y · Cited by 47
Pathogen evolution during vaccination campaigns
Day, T., Kennedy, D. A., Read, A. F., & Gandon, S. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001804 · Cited by 45
“, the dynamics of the Alpha and Delta variants of SARS-CoV-2 were driven by selection, not by the flux of mutations [12,13]).”
BackgroundAmellal, H., Assaid, N., Charoute, H., Akarid, K., Maaroufi, A., Ezzikouri, S., & Sarih, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288557 · Cited by 46
Kim, S., Kim, E.-H., Casel, M. A. B., Kim, Y., Sun, R., Kwak, M.-J., Yoo, J., Yu, M., Yu, K.-M., Jang, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113077 · Cited by 50
Meister, T. L., Fortmann, J., Tödt, D., Heinen, N., Ludwig, A., Brüggemann, Y., Elsner, C., Dittmer, U., Steinmann, J., Pfaender, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab260 · Cited by 36
“7 strain has been suspected to display a 43–90% higher reproduction number compared to preexisting variants [6].”
BackgroundFirst Detection of SARS-CoV-2 B.1.1.7 Variant of Concern in an Asymptomatic Dog in Spain
Barroso‐Arévalo, S., Rivera, B., Domínguez, L., & Sánchez‐Vizcaíno, J. M. (2021) · Viruses · doi:10.3390/v13071379 · Cited by 40
Halle, C., Robertson, A. H., Hungnes, O., Tunheim, G., Bekkevold, T., Laake, I., Aune, I. F., Killengreen, M. F., Strand, T. R., Rykkvin, R., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9112371 · Cited by 41
Trimpert, J., Adler, J. M., Eschke, K., Abdelgawad, A., Firsching, T. C., Ebert, N., Thao, T. T. N., Gruber, A. D., Thiel, V., Osterrieder, N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abk0172 · Cited by 43
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · medRxiv · doi:10.1101/2021.03.07.21253098 · Cited by 41
“The highest reduction observed for E484K, F484A, B.1.351 and P.1 were also approximately two-fold but this did not apply to all six vaccinees.”
InfluentialWang, K., Cao, Y., Zhou, Y., Wu, J., Jia, Z., Hu, Y., Yisimayi, A., Fu, W., Wang, L., Liu, P., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21261735 · Cited by 44
Slavov, S. N., Patané, J. S. L., Bezerra, R. D. S., Giovanetti, M., Fonseca, V., Martins, A. J., Viala, V. L., Rodrigues, E. S., Santos, E. V., Barros, C. R. S., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27190 · Cited by 51
Eales, O. D., Plank, M. J., Cowling, B. J., Howden, B. P., Kucharski, A. J., Sullivan, S. G., Vandemaele, K., Viboud, C. G., Riley, S., McCaw, J. M., et al. (2024) · Emerging infectious diseases · doi:10.3201/eid3002.230768 · Cited by 45
“This process also would enable estimation of the effective reproduction numbers of circulating variants during periods of variant replacement ( 47 ), improve real-time forecasts of variant outbreaks, and inform intervention planning.”
BackgroundSelf-citationDispersal dynamics of SARS-CoV-2 lineages during the first epidemic wave in New York City
Dellicour, S., Hong, S. L., Vrancken, B., Chaillon, A., Gill, M. S., Maurano, M. T., Ramaswami, S., Zappile, P., Marier, C., Harkins, G. W., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009571 · Cited by 39
“V1 are associated with a higher transmissibility [15,16], monitoring their colonization should be a top priority in the upcoming months.”
BackgroundRevisiting the guidelines for ending isolation for COVID-19 patients
Jeong, Y. D., Ejima, K., Kim, K. S., Iwanami, S., Bento, A. I., Fujita, Y., Jung, I. H., Aihara, K., Watashi, K., Miyazaki, T., et al. (2021) · eLife · doi:10.7554/elife.69340 · Cited by 42
Douglas, J., Geoghegan, J. L., Hadfield, J., Bouckaert, R., Storey, M., Ren, X., de Ligt, J., French, N. P., & Welch, D. (2021) · Emerging infectious diseases · doi:10.3201/eid2709.211097 · Cited by 38
Insight into COVID-19's epidemiology, pathology, and treatment
Aimrane, A., Laaradia, M. A., Séréno, D., Perrin, P., Draoui, A., Bougadir, B., Hadach, M., Zahir, M., Fdil, N., Hiba, O. E., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e08799 · Cited by 43
Xavier, C. R., Oliveira, R. S., Vieira, V. D. F., Lobosco, M., & dos Santos, R. W. (2022) · BioTech · doi:10.3390/biotech11020012 · Cited by 44
Do COVID-19 containment measures work? Evidence from Switzerland
Pleninger, R., Streicher, S., & Sturm, J. (2022) · Zeitschrift für schweizerische Statistik und Volkswirtschaft/Schweizerische Zeitschrift für Volkswirtschaft und Statistik/Swiss journal of economics and statistics · doi:10.1186/s41937-022-00083-7 · Cited by 46
“Second, the so-called UK-mutation B.1.1.7, or Alpha, a variant of SARS-CoV-2 that is clearly more transmissible than the wild-type, became more and more prevalent in Switzerland (Davies et al., 2021).”
BackgroundInfluentialAntibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
Javanmardi, K., Segall-Shapiro, T. H., Chou, C., Boutz, D. R., Olsen, R. J., Xie, X., Xia, H., Shi, P., Johnson, C. D., Annapareddy, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.016 · Cited by 42
COVID-19 Hospitalizations, ICU Admissions and Deaths Associated with the New Variants of Concern
Tuite, A. R., Fisman, D. N., Odutayo, A., Bobos, P., Allen, V. G., Bogoch, I. I., Brown, A. D., Evans, G. A., Greenberg, A., Hopkins, J. P., et al. (2021) · doi:10.47326/ocsat.2021.02.18.1.0 · Cited by 37
The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City
Cedro‐Tanda, A., Gómez-Romero, L., Alcaraz, N., de Anda‐Jáuregui, G., Peñaloza, F., Moreno, B., Escobar-Arrazola, M. A., Ramirez-Vega, O. A., Munguía-Garza, P., Garcia-Cardenas, F., et al. (2021) · Viruses · doi:10.3390/v13112182 · Cited by 35
Negi, S. S., Schein, C. H., & Braun, W. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-04950-4 · Cited by 36
Recent Progress on Rapid Lateral Flow Assay-Based Early Diagnosis of COVID-19
Zhang, Y., Chai, Y., Hu, Z., Xu, Z., Li, M., Chen, X., Yang, C., & Liu, J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.866368 · Cited by 45
Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic
González-Vázquez, L. D., & Arenas, M. (2023) · Genes · doi:10.3390/genes14020407 · Cited by 51
Evolution and implications of SARS-CoV-2 variants in the post-pandemic era
Manirambona, E., Okesanya, O. J., Olaleke, N. O., Oso, T. A., & Lucero‐Prisno, D. E. (2024) · Discover Public Health · doi:10.1186/s12982-024-00140-x · Cited by 45
Pandemic monitoring with global aircraft-based wastewater surveillance networks
St-Onge, G., Davis, J. T., Hébert‐Dufresne, L., Allard, A., Urbinati, A., Scarpino, S. V., Chinazzi, M., & Vespignani, A. (2025) · Nature Medicine · doi:10.1038/s41591-025-03501-4 · Cited by 42
Ong, S. W. X., Young, B. E., & Lye, D. C. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00201-2 · Cited by 37
A Highly Potent SARS-CoV-2 Blocking Lectin Protein
Ahan, R. E., Hanifehnezhad, A., Kehribar, E. Ş., Oğuzoğlu, T. Ç., Földes, K., Özçelik, C. E., Filazi, N., Öztop, S., Palaz, F., Önder, S., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00006 · Cited by 37
Metadata
- Authors
- Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T., Gimma, A., Waites, W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz, K., Keogh, R., Eggo, R. M., Funk, S., Jit, M., Atkins, K. E., & Edmunds, W. J.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- Selva Analytics LLC, Bozeman, MT, USA.
- KU Leuven (BE)
- Pennsylvania State University (US)
- Centre for Statistical Methodology and Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
- Corresponding author
- Davies, Nicholas G.
- ORCID
- Davies, Nicholas G.
- Abbott, Sam
- Barnard, Rosanna C.
- Jarvis, Christopher I.
- Kucharski, Adam J.
- Munday, James D.
- Pearson, Carl A. B.
- Russell, Timothy W.
- Tully, Damien C.
- Washburne, Alex D.
- Wenseleers, Tom
- Gimma, Amy
- Waites, William
- Wong, Kerry L. M.
- van Zandvoort, Kevin
- Silverman, Justin D.
- Diaz-Ordaz, Karla
- Keogh, Ruth
- Eggo, Rosalind M.
- Funk, Sebastian
- Jit, Mark
- Atkins, Katherine E.
- Edmunds, W. John
- Venue
- Science
- Published
- 2021-04-09
- Volume
- 372
- Issue
- 6538
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8128288
- OpenAlex
- W3134208712
- Semantic Scholar
- 34e9a0b4e42a4971a3a124c818045741c734fb9e
- Cited by
- 2,581
- References
- 58
- Citations by year
- 2026: 74 · 2025: 102 · 2024: 199 · 2023: 330 · 2022: 840 · 2021: 1028
- FWCI
- 215.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (submittedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion, cc-by)
- Northumbria Research Link (Northumbria University) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- University of Kentucky
- Universität Bern
- Universitätsspital Basel
- National Institute for Health Research (NIHR200908)
- European Commission (101003688)
- CANDU Owners Group
- Hôpitaux Universitaires de Genève
- Eidgenössische Technische Hochschule Zürich
- Université de Sfax
- UKRI Research England (NA)
- National Institute for Health Research Health Protection Research Unit in Immunisation (NIHR200929)
- United Kingdom Medical Research Council (MC_PC_19065)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- SARS-CoV-2, B.1.1.7 variant, reproduction number, SARS-CoV-2 transmission, epidemic forecasting, COVID-19 containment measures, vaccine rollout, school closures, England
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Communicable Disease Control, England, Europe, Female, Humans, Infant, Male, Middle Aged, Models, Theoretical, Mutation, Severity of Illness Index, Socioeconomic Factors, United States, Viral Load, Basic Reproduction Number, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.